2026-01-20 - Analysis Report
**Company Overview**
Estée Lauder Companies is a multinational cosmetics company.

**Return Rate Comparison**

| Stock Ticker | Cumulative Return |
| --- | --- |
| EL | -25.64% |
| VOO (S&P 500) | 93.30% |

**Divergence**
Current divergence: -118.90
Relative divergence: 8.90%

**Alpha, Beta Analysis**

| Period | CAGR | MDD | Alpha | Beta | Cap(B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 22.0% | 19.7% | 17.0% | 0.8 | 46.9B |
| 2017-2019 | 59.0% | 19.7% | 41.0% | 0.9 | 74.4B |
| 2018-2020 | 10.0% | 21.2% | -11.0% | 0.9 | 95.9B |
| 2019-2021 | 46.0% | 21.2% | 3.0% | 1.0 | 133.4B |
| 2020-2022 | -43.0% | 50.3% | -41.0% | 1.1 | 89.4B |
| 2021-2023 | -68.0% | 58.4% | -69.0% | 1.3 | 52.7B |
| 2022-2024 | -101.0% | 64.6% | -121.0% | 1.3 | 27.0B |
| 2023-2025 | -44.0% | 63.7% | -106.0% | 1.3 | 37.7B |

**Stock Price Fluctuations**

| Period | 5-day SMA | 20-day SMA | 60-day SMA | Close | Last-market |
| --- | --- | --- | --- | --- | --- |
| - | $115.20 | $109.67 | $100.60 | $115.05 | -$0.52 |

**RSI, PPO Index, and Expected Return**

| Indicator | Value |
| --- | --- |
| Market Risk Indicator (MRI) | 0.80 |
| RSI | 64.82 |
| PPO | 0.35 |
| Delta_Previous_Relative_Divergence | improving |
| 7-day Rank change | flat |
| 7-day Dynamic Expected Return change | flat |
| Expected Return | -763.40% |

**Recent News & Significant Events**

[2026-01-16] Estee Lauder Companies (NYSE:EL) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
[2025-12-19] The Estée Lauder Companies Inc. (NYSE:EL) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - simplywall.st
[2026-01-11] What Does The Estée Lauder Companies Inc.'s (NYSE:EL) Share Price Indicate? - Yahoo Finance
[2026-01-16] Estee Lauder (EL) Sees Analyst Ratings Boost by JP Morgan | EL S - GuruFocus
[2026-01-05] Raymond James Upgrades Estée Lauder Companies (EL) - Nasdaq
[2025-10-21] Estee Lauder Companies Stock To $73? - Trefis

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.42 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): 108.96 / 131.00 / 65.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-30 | 0.13 | $3.48 B |
| 2025-05-01 | 0.44 | $3.55 B |
| 2025-02-04 | -1.64 | $4.00 B |
| 2024-10-31 | -0.43 | $3.36 B |
| 2024-07-31 | 5.00 | 3.35 B$ |

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $3.48B | 73.37% |
| 2025-06-30 | $3.41B | 72.00% |
| 2025-03-31 | $3.55B | 74.96% |
| 2024-12-31 | $4.00B | 76.10% |
| 2024-09-30 | $3.36B | 72.39% |

**Capital and Profitability**

| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $3.89B | 1.21% |
| 2025-06-30 | $3.87B | -14.13% |
| 2025-03-31 | $4.34B | 3.66% |
| 2024-12-31 | $4.17B | -14.15% |
| 2024-09-30 | $5.08B | -3.07% |

**Comprehensive Analysis**
The stock performance is highly volatile, with a cumulative return of -25.64% compared to the S&P 500's 93.30%. The analysis suggests a high risk investment, with a market risk indicator of 0.80. The recent news and significant events indicate a positive sentiment, with analyst opinions supporting a buy. However, the earnings analysis shows a mixed performance, with a decline in revenue and EPS in the last quarter. The company's profitability has also been impacted, with a decline in profit margin and ROE in some quarters.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.